Table 7 Base case results

Clinical outcomes

Number of IPD cases

⋅ Bacteraemia

28,602

27,064

-1,539

⋅ Meningitis

1,345

1,247

-98

Number of pneumonia cases

⋅ With hospital contact

2,255,906

2,229,039

-26,867

⋅ Without hospital contact

2,794,766

2,764,617

-30,149

Number of deaths due to IPD

7,004

6,674

-330

Number of deaths due to pneumonia

122,412

121,357

-1,055

Life years gained

70,392,931

70,400,516

7,584

⋅ Life years per person

16.77

16.77

0.0018

QALYs gained

60,123,775

60,131,741

7,966

⋅ QALYs per person

14.32

14.33

0.0019

Economic outcomes (EUR)

Total costs

5,599,670,010

5,526,062,665

-73,607,345

⋅ Total costs per person

1,334

1,317

-17.54

Healthcare costs

⋅ Vaccination costs

35,453,377

102,654,202

67,200,826

⋅ Hospital sector

5,445,778,380

5,306,065,869

-139,712,512

⋅ Primary sector

118,438,253

117,342,594

-1,095,659

Cost-effectiveness

⋅ Incremental costs per life year gained

-9,705 (PCV20 is the dominant strategy)

⋅ Incremental costs per QALY gained

-9,240 (PSV20 is the dominant strategy)